LINCC Initiative to provide charitable contribution to 16 organizations to support individuals with HIV/AIDS

Editorial Checklist Reviewed
Janssen Pharmaceuticals, Inc.Apr 25 2013NewsGuard 100/100 Score

Janssen Therapeutics, Division of Janssen Products, LP, today announced the 16 organizations that will receive a charitable contribution from its Linking In-Need Communities to Care (LINCC™) Initiative. The LINCC™ Initiative is part of the Janssen Therapeutics commitment to improving access to care in underserved communities for those whose lives are impacted by HIV/AIDS.

The recipients for the 2012-2013 cycle each received charitable contributions of up to $30,000 in support of programs to address personal, societal and structural barriers to care for individuals diagnosed and living with HIV/AIDS. Since the LINCC™ Initiative began in 2010, Janssen Therapeutics has contributed nearly $1.6 million to 44 community-based HIV/AIDS organizations in rural and urban areas of unmet need.

During the past three years, LINCC™ funding has focused on the country's most at-risk populations for HIV infection according to the Centers for Disease Control and Prevention: women of color and African-American men who have sex with men. Activities supported through the LINCC™ Initiative cycle for 2012-2013 will also reach historically marginalized communities, such as incarcerated persons living with HIV/AIDS and the transgender community.

"The HIV epidemic is not going away and it often hits those in greatest need of care the hardest," said Carine Brouillon, President of Janssen Therapeutics. "We're proud that for the third year in row, the LINCC™ Initiative carries on our commitment to help improve access to care and health outcomes, while also addressing healthcare disparities among the HIV community."

Related Stories

This year's 16 recipients comprise a diverse range of organizations that serve HIV/AIDS communities across the United States including:

Source:

Janssen Pharmaceuticals, Inc.

Posted in: Disease/Infection News | Healthcare News

Tags: , , , , , , , , ,

Comments (0)

Suggested Reading

Sweden becomes first country to meet global HIV targets
Affordability and supply remain critical to the success of long-lasting HIV drug
Study uncovers mechanism of MX protein in fighting HIV-1 and herpes simplex virus
Georgetown University receives $27.5 million grant to combat HIV/AIDS in Haiti
Exclusion of indigenous voices hinders HIV progress in Latin America
New two-dose HIV vaccine strategy shows promise for stronger immune response
Historical redlining continues to affect HIV treatment in affected communities
Sweden exceeds UNAIDS HIV goals but faces new challenges

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New insights into the mechanisms of efavirenz-induced neurotoxicity